Scarica l'app Stockscreener
9.13
1.78%
0.16
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Zevra launches first FDA-approved NPC treatment - Investing.com India
Zevra Launches First FDA-Approved Treatment for Rare Niemann-Pick Disease | ZVRA Stock News - StockTitan
HC Wainwright Expects Lower Earnings for Zevra Therapeutics - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Guggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy Recommendation - MSN
Zevra Therapeutics (STU:1GDA) Enterprise Value : €424.12 Mil (As of Nov. 20, 2024) - GuruFocus.com
Zevra Therapeutics Q3 2024 Earnings Preview - MSN
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily
ZVRA FY2024 EPS Forecast Decreased by Cantor Fitzgerald - MarketBeat
What is William Blair's Forecast for ZVRA FY2024 Earnings? - MarketBeat
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report - Yahoo Finance
Zevra testing beta blocker celiprolol for vEDS in Phase 3 US study - Ehlers-Danlos News
Simplify Asset Management Inc. Invests $833,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
What is William Blair's Estimate for ZVRA FY2026 Earnings? - MarketBeat
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results - Simply Wall St
Roth Capital Forecasts Lower Earnings for Zevra Therapeutics - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Decline in Short Interest - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Zevra Therapeutics reports Q3 financial results - Investing.com
Canaccord Genuity Group Issues Pessimistic Forecast for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price - MarketBeat
Q4 Earnings Forecast for ZVRA Issued By Roth Capital - MarketBeat
Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com
Janney Montgomery Scott LLC Sells 127,755 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus.com
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
Zevra Therapeutics’ Transformative Third Quarter 2024 - TipRanks
Zevra Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Zevra Therapeutics earnings missed by $0.28, revenue fell short of estimates - Investing.com UK
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
Zevra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... By GuruFocus - Investing.com Canada
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - The Manila Times
Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Kn - GuruFocus.com
Zevra Therapeutics Validates Key Clinical Scale for Niemann-Pick Disease Treatment Study | ZVRA Stock News - StockTitan
International Assets Investment Management LLC Raises Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ZVRA stock touches 52-week high at $8.96 amid market rally - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $20.83 Average PT from Analysts - MarketBeat
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 - The Manila Times
Zevra Therapeutics CEO to Present at Guggenheim Healthcare Conference | ZVRA Stock News - StockTitan
Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Zevra Therapeutics Inc - GuruFocus.com
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - The Manila Times
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline - Yahoo Finance
How To Trade (ZVRA) - Stock Traders Daily
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury
Will Zevra Gallop Or Saunter In Q3? - RTTNews
Objective long/short (ZVRA) Report - Stock Traders Daily
Sanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra therapeutics director Corey Watton buys $3,957 in stock - Investing.com India
Zevra therapeutics director Corey Watton buys $3,957 in stock By Investing.com - Investing.com Australia
Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN
Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $20.83 - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Up 25.7% in September - MarketBeat
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):